Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr Haas on the Rationale for Evaluating Adjuvant Pembrolizumab in Clear Cell RCC

September 2nd 2025

Naomi B. Haas, MD, details the rationale for evaluating adjuvant pembrolizumab monotherapy for the treatment of patients with clear cell RCC.

Dr Hammers on Considerations for Assessing TKI/Immunotherapy Response in ccRCC

August 29th 2025

Hans Hammers, MD, PhD, discusses factors that may influence depth of response to IO/TKI or IO/IO therapy in advanced clear cell renal cell carcinoma.

Dr Vento on the Clinical Significance of Somatic NGS in Guiding Treatment Decisions for Non–Clear Cell RCC

August 27th 2025

Joseph Vento, MD, discusses the importance of using somatic NGS to guide treatment decision-making for patients with non–clear cell RCC.

Dr Chahoud on the Rationale for Evaluating Zanzalintinib Plus Nivolumab With/Without Relatlimab in ccRCC

August 20th 2025

Jad Chahoud, MD, MPH, discusses the background and rationale for evaluating zanzalintinib plus nivolumab with or without relatlimab in ccRCC.

Dr Vento on the Importance of Refining the Classification of RCC to Better Account for Molecular Heterogeneity

August 18th 2025

Joseph Vento, MD, discusses the importance of refining RCC classification standards to improve the field’s understanding of the disease’s heterogeneity.

Nemvaleukin Alfa Demonstrates Durable Disease Control in Advanced Melanoma and RCC

August 15th 2025

Nemvaleukin alfa produced a disease control rate of 50% in advanced melanoma and RCC.

Tailored Therapies Needed to Overcome Immune-Cold Microenvironment of Chromophobe RCC

August 15th 2025

David A. Braun, MD, PhD, discusses the need for more tailored treatments that improve tumor-specific T-cell infiltration in chromophobe RCC.

Defects in Antitumor Immunity May Account for Limited Efficacy With Checkpoint Inhibition in Chromophobe RCC

August 14th 2025

David A. Braun, MD, PhD, outlines differences in the tumor biology and immune phenotypes of chromophobe and clear cell renal cell carcinoma.

Dr Pal on Future Research Directions With Adjuvant Immunotherapy in High-Risk Resected RCC

August 12th 2025

Sumanta Kumar Pal, MD, FASCO, discusses future directions using genomic data from the phase 3 IMmotion010 trial.

Dr Pal on the Predictive Utility of KIM-1 Expression in High-Risk Resected RCC

August 12th 2025

Sumanta Kumar Pal, MD, FASCO, discusses data supporting KIM-1 as a potential biomarker to inform adjuvant immunotherapy use in high-risk resected RCC.

Five Under 5: Top Oncology Videos for the Week of 8/3

August 10th 2025

The top 5 OncLive videos of the week cover insights in renal cell carcinoma, glioma, multiple myeloma, and ovarian cancer.

Chromophobe RCC Microenvironment Study Shows Determinants of Impaired Antitumor Immunity

August 8th 2025

Although chromophobe RCC has an immune-cold environment, ferroptosis induction may be a promising target for managing tumor resistance in this subtype.

Serum KIM-1 Emerges as Potential Biomarker to Guide Adjuvant Immunotherapy in High-Risk Resected RCC

August 5th 2025

Sumanta Kumar Pal, MD, FASCO, discusses findings from a genomic analysis of patients with high-risk, resected RCC treated with checkpoint inhibitors.

Dr Haas on Evolutions in Clinical Trial Design in the RCC Treatment Paradigm

August 4th 2025

Naomi B. Haas, MD, discusses previously conducted trials that supported the initiation of the KEYNOTE-564 trial of adjuvant pembrolizumab in RCC.

Dr Tan on the Ongoing Investigation of Adaptive Treatment Intensification Strategies in RCC

August 1st 2025

Alan Tan, MD, discusses current and future avenues for evaluating adaptive immunotherapy approaches in treatment-naive metastatic RCC.

Dr Tan on the Rationale for Evaluating an Adaptive Immunotherapy Strategy in Previously Untreated RCC

August 1st 2025

Alan Tan, MD, discusses the rationale for evaluating an adaptive approach to immunotherapy de-escalation in patients with RCC achieving a CR.

Dr Braun on Fundamental Immune Defects in Chromophobe RCC

July 31st 2025

David A. Braun, MD, PhD, discusses immune defects in patients with chromophobe RCC vs clear cell RCC.

Dr Jacob on the Potential Role for TAR-200 in BCG-Unresponsive, High Risk NMIBC

July 31st 2025

Joseph Jacob, MD, MCR, discusses the potential role of an intravesical gemcitabine delivery system for BCG-unresponsive non–muscle-invasive bladder cancer.

Immunotherapy Sequencing Must Be Personalized During Therapy Selection for Metastatic RCC

July 28th 2025

Alan Tan, MD, discusses how a trial analysis of ipilimumab plus nivolumab in metastatic ccRCC informs strategies for optimal immunotherapy sequencing.

Five Under 5: Top Oncology Videos for the Week of 7/13

July 20th 2025

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.